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NGOING  DEBATES  IN  THE  PHARMACEUTICAL 
sector about intellectual property,1,2 pricing 
and  reimbursement,3,4  and  public  research 
investments5 have a common denominator: the pur-
suit of innovation. However, there is little clarity about 
what  constitutes  a  true  pharmaceutical  innovation, 
and as a result there is confusion about what kind of 
new  products should  be pursued,  protected  and  en-
couraged through health policy and clinical practice.6 
If  the  concept  of  pharmaceutical  innovation  can  be 
clarified, then it may become easier for health policy-
makers and practitioners to evaluate, adopt and pro-
cure  products  in  ways  that  appropriately  recognize, 
encourage and give priority to truly valuable pharma-
ceutical innovations.  
  To describe a product as innovative implies that it 
has properties that are worthy of recognition and re-
ward. The term suggests that the product has unique 
value. However, notions of value are a matter of per-
spective. Commercial value, for example, is generally 
assessed from the perspective of a firm’s profitability. 
The perceived societal value of ordinary goods is often 
defined by consumer preferences as reflected by their 
willingness to pay for products that they perceive to be 
“good  value  for  money.”  However,  pharmaceuticals 
are not ordinary goods. 
  Pharmaceutical products have no intrinsic value to 
patients or to society; rather, their value lies in the 
health outcomes they generate. Pharmaceuticals are 
licensed for sale on the basis of whether they safely 
and efficaciously address a health care need, not be-
cause  patients  might  have  preferences  concerning 
their shape, colour, taste or brand. Although charac-
teristics like shape, colour, taste or brand may play a 
role in improving health outcomes — perhaps by in-
creasing treatment adherence — it is the measurable 
improvements  in  health  outcomes  that  generate 
value  for  society.  Product  characteristics  are  analo-
gous to surrogate endpoints in clinical trials insofar 
as they are of societal  value  only to the extent that 
they predict clinical or “hard” endpoints.7,8 
  Although the concepts of  novelty and innovation 
are often associated with one another,9 defining the 
societal value of pharmaceuticals exclusively in terms 
of  the  production  of  health  outcomes  implies  that 
product  novelty  alone  does  not  constitute  pharma-
ceutical  innovation.  New  chemical  structures  or 
mechanisms  of  action  do  not  necessarily  generate 
improved health outcomes:10,11 a new pharmaceutical 
product must also have some degree of effectiveness 
(net of treatment risks).6 It should be noted that ef-
fectiveness  alone  is  not  enough  to  qualify  a  new 
product as an innovation. A generic drug, for exam-
ple,  may  safely  and  efficaciously  address  a  health 
care need — and may provide value to patients and 
society — but it would hardly be considered an inno-
vation. Thus, neither novelty nor effectiveness alone 
is  enough  to  qualify  as  pharmaceutical  innovation. 
Even the combination of novelty and effectiveness is 
not enough. 
  Pharmaceutical innovation requires novelty of effec-
tiveness.  Pharmaceutical  innovations  create  value  to 
society by making it possible to generate improvements 
in patient health (net of treatment risks) that were pre-
viously unattainable. It is the uniqueness of such health 
improvements  that  defines  pharmaceutical  innova-
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tions. A drug can be considered a pharmaceutical inno-
vation only if it meets otherwise unmet or inadequately 
met health care needs. This will depend on its efficacy, 
safety and convenience of use relative to the technolo-
gies  available  when  it  is  introduced.  For  example, 
cimetidine,  the  prototypical  histamine-2  receptor  an-
tagonist, was considered a pharmaceutical innovation 
when it was introduced in 1977 because it safely and ef-
fectively  addressed  a  previously  inadequately  met 
need.12 However, the notion of pharmaceutical innova-
tion is time-dependent. Competition and technological 
change  mean  that  the  standard  by  which  the  unique 
value  of  a  pharmaceutical  innovation  is  measured  — 
the ability to address health care needs that are other-
wise not addressable — will change over time. Neither 
cimetidine nor other histamine-2 receptor antagonists 
would  be  considered  innovations  today  because  the 
outcomes they generate have been matched and even 
surpassed by other technologies. 
  Replicating  outcomes  obtainable  with  existing 
treatments is important for market competition but 
it does not represent innovation. However, surpass-
ing  existing  levels  of  performance  in  terms  of 
established efficacy, safety or both would be consid-
ered  pharmaceutical  innovation.  Again,  consider 
advances in gastroenterology: the first proton pump 
inhibitor, omeprazole, was an innovation when it was 
introduced in 1989 because it met a given need more 
effectively  than  histamine-2  receptor  antagonists. 
Proton pump inhibitors have since become the main-
stay  of  treatment  for  acid-related  gastrointestinal 
disease in adults. Although they continue to generate 
valuable outcomes, they would no longer be consid-
ered innovations. 
  A pharmaceutical innovation may be thought of as 
incremental, substantial  or radical according to the 
significance  of  the  unmet  health  care  need  it  ad-
dresses  (gravity  of  unmet  need)  and  the  extent  to 
which it improves net health outcomes related to that 
need  (comparative  effectiveness)  (Figure  1).  The 
gravity of an unmet need can be thought of as the gap 
between  the  health  status  that  patients  with  a  par-
ticular  medical  condition  could  attain  with  existing 
technologies and the health status they could expect 
if they did not have that medical condition. The low-
est gravity of unmet need (a value of zero) represents 
cases in which patients experience no deprivation in 
health  status  if  they  receive  existing  treatments  or 
cases in which the nature of the condition is trivial in 
terms of health status (e.g., male pattern baldness). 
The highest gravity of unmet need (a value of 1) rep-
resents cases in which the condition has a prognosis 
of immediate death given existing treatment options. 
  Gravity  of  unmet  need  establishes  the  potential 
for  pharmaceutical  innovation  (i.e.,  the  maximum 
improvement in health status that a new drug might 
offer,  over  and above  existing technologies).  For  a 
condition with a low gravity of unmet need, such as 
colour  blindness,  there  is  a  limited  potential  for 
pharmaceutical innovation. To determine the  level 
of  pharmaceutical  innovation  that  a  drug  actually 
achieves, one must also examine its comparative ef-
fectiveness in terms of net improvements in health 
outcomes, taking into account the negative effects of 
the  drug  (e.g.,  side  effects  and  adverse  events). 
Drugs with zero comparative effectiveness offer no 
improvement in health outcomes compared with ex-
isting treatments. The highest possible comparative 
effectiveness (a value of 1) indicates the ideal (and 
seldom, if ever, realized) situation in which a drug is 
perfectly  safe  and  entirely  closes  the  gap  between 
the  health  status  attainable  with  prevailing  treat-
ments  and  the  ideal  health  status  for  the  treated 
population. The categories of innovation in Figure 1 
are drawn with a lower border because a medicine 
must offer some level of comparative health benefit 
to  be  considered  an  innovation,  no  matter  how 
grave the condition it aims to remedy. 
  The  greater  the  gravity  of  the  unmet  need  ad-
dressed  by  a  new  treatment,  or  the  greater  its 
comparative  effectiveness  in  addressing  that  need, 
the greater the degree of pharmaceutical innovation. 
Radical innovations, or “breakthroughs,” are moder-
ately  to  highly  effective  treatments  for  conditions 
that would otherwise significantly reduce the quality 
or length of life or both, or treatments that provide a 
near-total cure in cases in which the prevailing un-
met  needs  are  more  moderate.  Substantial 
innovations  offer  fair  to  modest  improvements  in 
health  outcomes  for  patients  with  grave  unmet 
needs,  or  substantial  improvements  over  existing 
treatments  for  patients  whose  unmet  health  care 
needs  are less serious. Finally, incremental innova-
tions  offer  minor  to  moderate  improvements  over 
existing treatments for patients whose unmet needs 
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  Breakthrough  drugs  (or  radical  pharmaceutical 
innovations)  generate  the  most  significant  societal 
value  through  their  unique  ability  to  generate  im-
provements  in  health  outcomes  not  otherwise 
possible. To qualify as a breakthrough, a new drug 
must  offer  significant  improvements  over  existing 
treatments, even when the prevailing unmet needs 
are  dire.  For  example,  a  drug  that  briefly  extends 
the  life  expectancy  of  terminally  ill  patients  might 
be considered an innovation, but to be considered a 
breakthrough  it  would  have  to  provide  these  pa-
tients  with  a  quantity  and  quality  of  life  close  to 
what they could have expected in the absence of the 
underlying  illness.  For  this  reason,  the  break-
through category does not intersect with the lower 
horizontal line of Figure 1. 
  There is limited scope for pharmaceutical innova-
tion for conditions for which existing therapies offer 
relatively good outcomes. New treatments within a 
drug class may offer modest therapeutic gains in ef-
ficacy or safety, but being different does not in itself 
constitute  innovation.  For  example,  early  and  late 
entrants into a drug class might each be more effec-
tive  or  better  tolerated  among  certain  population 
subgroups.  However,  late  entrants  will  not  repre-
sent  significant  pharmaceutical  innovation  unless 
they are systematically superior to early ones. 
  The  value  of  new  drugs  that  produce  outcomes 
similar to those achievable with other treatment op-
tions  lies  not  in  innovation  but  in  the  potential 
competition  that  these  products  may  bring  to  the 
marketplace. Such competition may have value for 
consumers and  for  society  more  generally  through 
reduced costs per outcome achieved. However, the 
cost of developing such medicines includes the sig-
nificant investment and the risks to participants in 
various stages of clinical trials, as well as the funds 
spent on marketing efforts to differentiate the new 
drug from existing treatments, and all of these costs 
divert  resources  from  the  pursuit  of  treatments  to 
meet more substantial unmet health needs.1,13,14  
  Ultimately, it is commercial  value that drives in-
vestments and activities in the private sector. Firms 
may strive for commercial performance by develop-
ing drugs that effectively address grave, unmet health 
care needs. Firms may also be commercially innova-
tive without generating pharmaceutical innovations, 
such  as  when  they  develop  a  marketing  campaign 
that builds brand loyalty for a product that is compa-
rable to existing alternatives. Indeed, when Figure 1 
is viewed from a societal perspective on a global or 
national basis, it appears that most of the commer-
cial activity in the pharmaceutical market is focused 
on  product  development  and  related  marketing  ac-
tivities  in  therapeutic  areas  in  which  new  products 
would at best provide incremental advances in popu-
lation health. That is, much of the innovation in this 
sector is commercial, not pharmaceutical. 
  The  fact  that  commercial  incentives  are  not  al-
ways  aligned  with  the  production  of  major 
pharmaceutical  innovations  is  evident  not  only  in 
the global divide between burden of illness and drug 
research and development,15,16 but also in the share 
of  product  development,  marketing  and  sales  in 
wealthy countries that is accounted for by medicines 
that  offer  little  or  no  advantage  over  established 
treatment  alternatives.17  Between  1993  and  2004, 
only  one-third  of US  applications for  the  licensing 
of new molecular entities were promising enough to 
qualify  for  priority  review  by  the  US  Food  and 
Drugs  Administration.18  The  proportion  of  new 
drugs  that  represent  true  breakthroughs  is  likely 
lower. Between 1981 and 2000, Prescrire Interna-
tional rated only 74 (3%) of nearly 2300 new drugs 
or  new  indications  for  existing  drugs  as  major  or 
important  therapeutic  gains.19  Fewer  than  10%  of 
recently developed biotechnology drugs and cancer 
treatments  have  been  deemed  to  offer  substantial 
Figure 1: A model of pharmacological innovation    
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improvements  with  respect  to  hard  clinical  end-
points.20,21 
  Ultimately, the pharmaceutical industry is not to 
blame.  The  industry’s  focus  on  research  and  mar-
keting  activities  for  products  that  do  not 
dramatically  advance  attainable  health  outcomes 
results from  the way drugs are  appraised, selected 
and  purchased  by  health  practitioners,  patients, 
policy-makers and insurers. If these actors placed a 
premium  on  true  pharmaceutical  innovation—
demonstrably safe and effective treatments for pre-
viously  unmet  needs—and  encouraged competition 
among technologies that produce equivalent health 
outcomes, private investments in research and de-
velopment  would  be  stimulated  in  the  areas  of 
greatest value to society.4  
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